SPEX Spherix die Chance des Jahres!!! FDA Zulassung für hochwirksame Ekzeme Mittel: BioLexa bringt d - 500 Beiträge pro Seite

[schatzFINDER]

Die Geheimperle des Jahres schlechthin!!!!

Spherix Beteiligung: Hoth Therapeutics 6.800.000 Aktien

https://hoththerapeutics.com/2017/07/03/spherix-inc-announce…

US FDA Zulassung für das hochwirksame Ekzeme Mittel sollte in kürze kommen

Patent bereits erteilt!!!

https://hoththerapeutics.com/2017/12/04/hoth-therapeutics-in…

Durch die Kombination von zwei bereits Zugelassenen Wirkstoffen dauert die Zulassung nur 1/3 bis 1/4 der normalen Zulassungsdauer

https://www.fda.gov/downloads/drugs/guidancecomplianceregula…

Hier die neuste offizielle Präsentation von Hoth Therapeutics

https://hoththerapeutics.com/wp-content/uploads/2018/01/pres…

Ekzeme Umsatz allein auf dem US Markt über 9 Mrd. Dollar mit 32 Millionen betroffene Menschen alleine in den USA

und jetzt zu Spherix

US Kürzel SPEX

Ausgegebene Aktien zum 30.06.2018 8.542.530

Spherix ist in Besitz von über 400 Patente im Bereich Kommunikation/Biotechnologie

http://spherix.com/

https://hoththerapeutics.com/

[schatzFINDER]

[KHL911]

Schon wieder so ein PushPfusch, Spherix war ja schon öfter dran, beim durch Dorf gescheucht werden 🤣🤣

[schatzFINDER]

Antwort auf Beitrag Nr.: 58.576.520 von KHL911 am 30.08.18 21:39:08

Ist es nicht. Letztes Jahr waren bis zu 500% in einer Woche realisierbar

Nachrichten sind bald in Anmarsch. In letzten 2 Monaten über 2 Millionen Stück ohne Nachrichten gekauft worden.

[schatzFINDER]

Spherix to Merge with CBM BioPharma Pharmaceutical Company
Print
Alert
Spherix (NASDAQ:SPEX)
Intraday Stock Chart
Today : Thursday 11 October 2018

Click Here for more Spherix Charts.
NEW YORK, Oct. 11, 2018 /PRNewswire/ -- Spherix Incorporated (Nasdaq: SPEX) today announced that it has entered into a merger agreement with CBM BioPharma, Inc. ("CBM") that will transform Spherix into an innovative pharmaceutical company with pioneering drugs and treatments focused on the multibillion dollar oncology therapeutics market.

Spherix Logo. (PRNewsFoto/Spherix Incorporated)

CBM is a privately held pharmaceutical company with exclusive drug development rights from world-renowned partners including Wake Forest Innovations and the University of Texas at Austin. CBM has a team of leading drug development scientists who will be joining Spherix as advisors to advance the technology. The CBM platform focuses on the treatment of numerous cancers, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and pancreatic cancer.

Two specific proprietary drugs that are currently being researched are:

KPC34 (Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

Developed at Wake Forest School of Medicine, AML and ALL drug, KPC34, is a next generation treatment designed to overcome multiple resistance challenges observed with the current standard of care. KPC34 has also been shown to be more effective in AML relapse cases, notably increasing the lifespan of mice treated with the drug.

One competitive benefit of KPC34 includes its ability to be orally administered. This is critical for patients that are unable to tolerate repeated cycles of chemotherapy. In addition, it has served to double the mean survival time of patients versus the current standard of care treatments.

DHA-dFdC (Pancreatic Cancer Drug)

Developed at the University of Texas at Austin, DHA-dFdC has shown positive results in preclinical studies, inhibiting pancreatic tumor growth in clinically relevant transgenic mouse models. DHA-dFdC also overcomes tumor cell resistance to current chemotherapeutic drugs. Pancreatic cancer is a deadly disease that affects millions of people around the world.

The following doctors will be supporting the efforts of Spherix, after the completion of the merger:

Dr. Timothy S. Pardee, MD, PhD, an Associate Professor of Internal Medicine, Section on Hematology and Oncology and Cancer Biology and Director of Leukemia Translational Research at Wake Forest School of Medicine. Dr. Pardee stated, "I am very excited at the possibility of bringing KPC34 to the clinic in early phase clinical trials. As a physician scientist who treats acute leukemia patients, I know firsthand the clear unmet medical need for relapsed patients."

Dr. Gregory Kucera, a Professor of Internal Medicine at the Wake Forest University School of Medicine with over 28 years of research experience on novel therapeutics for cancer treatment. His laboratory has expertise in synthesizing therapeutics, lipid biochemistry, and in vitro drug testing. Dr. Kucera stated, "As a research scientist, the satisfaction of seeing a compound like KPC34 go from the laboratory to an early stage clinical trial is immense. I have a great sense of pride in knowing that the work done by our research team has produced a drug that may benefit cancer patients in the very near future."

Joining Spherix as Chief Science Officer to oversee clinical advancement of these drugs is Dr. Tom Wilkie who is an Associate Professor of Pharmacology at the University of Texas Southwestern Medical Center in Dallas. He earned both his BA at the University of California Berkeley and his PhD with Richard Palmiter at UW Seattle, in biochemistry. Wilkie has published 74 primary research papers and reviews, serves on NIH, CIRM, and AACR grant review study sections. He reviews manuscripts for multiple journals, and is Director of the first-year graduate student core course at UT Southwestern.

Dr. Wilkie stated, "I'm delighted to join Spherix as Chief Science Officer. The agreement between Spherix Incorporated and CBM BioPharma will advance the exciting potential for improving the lives of patients, family, friends, and ultimately, all of us. Proposals for the next phase of testing are underway."

Dr. Robert J. Vander Zanden, Spherix's Chairman of the Board, stated, "Spherix is extremely pleased to announce this merger with CBM, as we believe it serves as a necessary step in our transition to a diversified biopharmaceutical company. This deal builds upon our investment in Hoth Therapeutics, which owns several exciting assets in various stages of development."

Anthony Hayes, CEO of Spherix stated, "We are very excited to welcome CBM BioPharma and its team to Spherix. It is an exciting and transformational time for the Company. Spherix will pay $16.5 million in stock for 100% of CBM by issuing 15 million Spherix shares to CBM at a fixed price of $1.10 per share. I look forward to sharing more information with our shareholders about the merger in the upcoming weeks, via investor outreach and our upcoming SEC filings."

About Spherix

Spherix is committed to advancing innovation by active participation in all areas of the patent market. Spherix draws on portfolios of pioneering technology patents to partner with and support product innovation. Spherix has acquired over 100 patents from Rockstar Consortium Inc., and several hundred patents issued to Harris Corporation, covering a variety of methods and components involved in switching, routing, networking, optical and telecommunication sectors.

About CBM BioPharma, Inc.

CBM BioPharma, Inc. (www.cbmbiopharmainc.com) is a privately held pharmaceutical company with exclusive drug development rights from world renowned partners like Wake Forest University and University of Texas. The Company has a team of leading drug development scientists who help advance their technology. The CBM platform focuses on the treatment of numerous cancers, including acute myeloid leukemia (AML), Acute Lymphoblastic Leukemia (ALL) and pancreatic cancer.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the SEC, not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact:

Investor Relations:

Hayden IR


Brett Maas, Managing Partner


Phone: [phone]


Email: [e-mail]


www.haydenir.com



Spherix:

Phone: [phone]


Email: [e-mail]


www.spherix.com



Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/spherix-to-merge-wit…

SOURCE Spherix Incorporated

[schatzFINDER]

https://ih.advfn.com/p.php?pid=nmona&article=78443940

[schatzFINDER]

Diese Fusion dürfte den Kurs beflügeln 👍 wird auch Zeit hier

[schatzFINDER]

[schatzFINDER]

https://youtu.be/-HRqzfdxaHQ

[schatzFINDER]

CBM BioPharma, Inc
CBM BioPharma, Inc (cbmbiopharmainc.com) is a privately held pharmaceutical company with exclusive drug development rights from world renowned partners like Wake Forest University and University of Texas. The Company has a team of leading drug development scientists who help advance their technology. The CBM BioPharma, Inc platform focuses on the treatment of numerous cancers, including acute myeloid leukemia (AML), Acute Lymphoblastic Leukemia (ALL) and pancreatic cancer.



Two specific proprietary drugs that are currently being researched are:
KPC34 (Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia)

Developed at Wake Forest School of Medicine, AML and ALL drug, KPC34, is a next generation treatment designed to overcome multiple resistance challenges observed with the current standard of care. KPC34 has also been shown to be more effective in AML relapse cases, notably increasing the lifespan of mice treated with the drug. One competitive benefit of KPC34 includes its ability to be orally administered. This is critical for patients that are unable to tolerate repeated cycles of chemotherapy. In addition, it has served to double the mean survival time of patients versus the current standard of care treatments.

DHA-dFdC (Pancreatic Cancer Drug)

Developed at the University of Texas at Austin, DHA-dFdC has shown positive results in preclinical studies, inhibiting pancreatic tumor growth in clinically relevant transgenic mouse models. DHA-dFdC also overcomes tumor cell resistance to current chemotherapeutic drugs. Pancreatic cancer is a deadly disease that affects millions of people around the world.

Video A significant number of acute lymphoblastic leukemia (ALL) patients will suffer from central nervous system involvement of their leukemia. This mouse model of ALL spreads to the central nervous system of mice causing hind limb paralysis. Repeated treatment with KPC34 showed an improvement of this in several test animals treated at Wake Forest. This video demonstrates one such test subject. These results demonstrate the potential of KPC34 to treat leukemia that has spread to the nervous system.



Published Papers
KPC-34
Kucera Paper A novel phospholipid gemcitabine conjugate is able to bypass three drug-resistance mechanisms

Kucera Paper Lipid Nucleoside Conjugates for the Treatment of Cancer

Kucers & Pardee Paper Improving Nucleoside Analogs via Lipid Conjugation

Short Summary of KPC34

The Phospholipid Gemcitabine Conjugate, KPC34, is a Novel Treatment for Leukemia

Wake Forest School of Medicine Study Phospholipiddeoxycytidine analogue prodrugs for the treatment of cancer


DHA-dFdC
Short-term Toxicity Study of DHA-dFdC

Study of DHA-dFdC

Synthesis and Cytotoxic Activity of Two Novel 1-Dodecylthio-2-decyloxypropyl-3-phosphatidic Acid Conjugates with Gemcitabine and Cytosine Arabinoside

[schatzFINDER]

http://www.spherix.com/cbm-biopharma.php

[schatzFINDER]

Heute Nacht beim stöbern eine sehr wichtige Meldung entdeckt.

Hoth Therapeutics geht an die Börse Nasdaq mit dem Kürzel: HOTH

Hier das Verkaufsprospekt:

https://www.sec.gov/Archives/edgar/data/1711786/000161577418…

Zeichnungsspanne 5,50 - 6,50 US Dollar.

Spherix besitzt laut dem Verkaufsprospekt 2.518.518 HOTH Aktien bei 6,00 Dollar sind es 15.100.000,00 Dollar. Spherix selbst ist mit Schlusskurs gestern 8.543.000 Aktien 0,85 US Dollar 7.261.550 US Dollar wert.

Alleine der Wert HOTH Aktien müsste den SPEX Kurs auf 1,76 US Dollar steigen lassen dazu die anderen Assets. 2,50 bis 3,00 Dollar sind hier ein realistischer Kurs.